Abstract: Gestational metabolic syndrome (GMS) is a cluster of multiple metabolic disorders during
pregnancy, including abnormal body mass, dysglycemia, dyslipidemia and hypertension, which will lead to adverse
pregnancy outcomes such as gestational diabetes mellitus (GDM), preeclampsia, fetal intrauterine growth restriction
and so on. The incidence of GMS increases yearly. At present, the research of GMS is mainly focused on the
diagnostic criteria and risk factors. However, the mechanism of GMS and its prevention strategy are lack of further
research. Visfatin, a kind of adipocytokines, is mainly expressed in and secreted from visceral adipose tissue.
Visfatin plays a role in the metabolism of glucose and lipid. It was found that visfatin participated in insulin
resistance, inflammatory reaction, cell apoptosis, atherosclerosis and vascular endothelial injury. Recent studies
have indicated that visfatin is closely related to the pathogenesis of GMS.